Understanding fatty acids in pancreatic tumors
Fatty acid signaling in the pancreatic tumor microenvironment
['FUNDING_R01'] · SLOAN-KETTERING INST CAN RESEARCH · NIH-11078800
This research explores how certain fats in pancreatic tumors affect the body's immune response, aiming to discover new ways to fight this cancer.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | SLOAN-KETTERING INST CAN RESEARCH (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-11078800 on ClinicalTrials.gov |
What this research studies
Pancreatic cancer is very difficult to treat, and current therapies often don't work well for many patients. This project looks at how specific molecules, like a protein called GOT2 and a fatty acid, create an environment where the body's immune cells struggle to attack the tumor. By understanding how these molecules help the cancer hide from the immune system, researchers hope to find new targets for treatments. The goal is to develop therapies that can make the immune system more effective against pancreatic cancer, potentially leading to better outcomes for patients.
Who could benefit from this research
Good fit: Patients with pancreatic ductal adenocarcinoma (PDAC) who are seeking new treatment approaches may eventually benefit from this research.
Not a fit: Patients with other types of cancer or those not seeking new immune-modulatory therapies for PDAC may not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to new immune-boosting treatments for pancreatic cancer, offering more effective options for patients.
How similar studies have performed: This research builds upon recent findings about specific molecular pathways, suggesting a novel approach to targeting pancreatic cancer's immune evasion.
Where this research is happening
NEW YORK, UNITED STATES
- SLOAN-KETTERING INST CAN RESEARCH — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SHERMAN, MARA H. — SLOAN-KETTERING INST CAN RESEARCH
- Study coordinator: SHERMAN, MARA H.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Cancer Agents